Navigation Links
Berg Pharma Presents Key Findings in Cancer Systems Biology and Mitochondrial Metabolism at AACR Meeting
Date:4/4/2012

CHICAGO, April 4, 2012 /PRNewswire/ -- Berg Pharma, a Boston based pharmaceutical company presented novel data today pertaining to key insights into cancer cell metabolism at the 103rd Annual AACR meeting.  The company had a total of 5 presentations at the meeting that dealt with endothelial cell biology relative to tumor angiogenesis, mitochondrial flux in cancer cells for priming of cancer therapy, synergy of BPM 31510, Berg's lead oncology drug in development with gemcitabine, and use of Interrogative Biology® for cancer systems biology. BPM 31510 is now in Phase I trials for advanced, refractory solid tumors and the company plans to commence Phase III trials with the topical form of the technology for squamous cell carcinoma this year.

(Logo:  http://photos.prnewswire.com/prnh/20120404/CL82745LOGO )

Seth Corey, MD, Director of the Center for Drug Development at Children's Memorial Research Center and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University called the systems biology approach, "most revolutionary technology in medicine today." He added, "given what we know of tumor heterogeneity and complexity, the systems approach and cancer metabolism as the target together offer the surest path to more effective therapies."

The research team employed the Interrogative Biology® discovery platform which takes an agnostic approach to biological modeling where systems models with disease-relevant perturbations and microenvironments are subjected to AI-Bayesian algorithms.  The generated output then teases out disease-normal nodal signatures which reflect pathological pressure points.  These are then used to identify and validate biomarkers and therapeutic targets to expedite the drug development process. This novel approach from the Berg Interrogative Biology® technology pla
'/>"/>

SOURCE Berg Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  QB3@953—a San ... University of California (UC) research institute and biotech ... GSK to identify and facilitate collaborations to translate ... patients. The agreement formalizes a relationship ... (DPAc) team and creates a new channel for ...
(Date:8/27/2015)... , Aug. 27, 2015  SciClone Pharmaceuticals, Inc. (NASDAQ: ... Chief Executive Officer, will present a corporate overview and business ... New York City . , 22 ... 11:30 am ET at the Millennium Broadway Hotel. , ... pm ET at the St. Regis Hotel. To ...
(Date:8/26/2015)... , Aug. 26, 2015 The North ... witness a CAGR of 7.8% during the forecast period, ... ophthalmology cataract surgery devices market in 2014 and accounted ... ophthalmology cataract surgery devices market is expected to witness ... the increasing strategic expansion of the companies and continuous ...
Breaking Medicine Technology:QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2SciClone To Present At Two Investor Conferences On September 10, 2015 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 3
... 14 Solta Medical, Inc. (Nasdaq: SLTM ), the pioneer ... announced it has received FDA 510(k) clearance for the new ... Fraxel re:store Dual system takes the industry leading ... 1927 nm wavelength, the first ever application of a Thulium laser ...
... 14 Par Pharmaceutical Companies, Inc. (NYSE: PRX ) ... tender offer for a portion of its outstanding 2.875% Senior ... "Modified Dutch Auction" procedure, Par is offering to purchase, for ... up to approximately 82.7%, of the outstanding convertible notes, at ...
Cached Medicine Technology:Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 2Solta Medical Announces FDA 510(k) Clearance of New Fraxel re:store(R) Dual Laser System 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 2Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 3Par Pharmaceutical Announces 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010 4
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a leading provider ... content is ICD-10 ready and available to all clients. All Krames Patient Education ... which are more targeted and return a more comprehensive data set of content ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... its partnership with Julia Glushko, professional Tennis player for Israel in the Women’s ... Zensah® Compression for all her training and recovery. , With a focus on ...
(Date:8/27/2015)... ... 2015 , ... In addition to its existing Doctor of Philosophy in Leadership ... at its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor ... practice nurses for the highest level of clinical nursing practice. , “Our vision ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... , ... August 27, 2015 ... ... Swan Analysis signed a partnership agreement for quality market research promotion on ... elaborated by Black Swan Analysis. , Commenting on the partnership agreement, Natalie ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... -- A new research study conducted by an international team ... including evidence-based guidelines for lower-risk use - to reduce the ... Led by CAMH scientist and CIHR/PHAC* Chair in Applied ... study is being published in the September/October 2011 issue of ...
... of medicines commonly given for pain -- were associated with ... adults, aged 65 to 94, e-published in advance of publication ... The study from researchers at Group Health Research Institute and ... are drugs generally given for insomnia and anxiety, did not ...
... , THURSDAY, Sept. 22 (HealthDay News) -- There ... and other recreational water in the United States in ... to two federal reports released Thursday. The 134 ... and December 2008 occurred in 38 states and Puerto ...
... HealthDay Reporter , THURSDAY, Sept. 22 (HealthDay News) -- ... prostate biopsy are hospitalized within 30 days of the procedure, ... of similarly aged men who do not get prostate biopsies can ... issue of the Journal of Urology . "The overall ...
... By Steven Reinberg HealthDay Reporter , ... containing chloroflouorocarbons (CFCs), which can damage the ozone layer, ... the U.S. Food and Drug Administration announced Thursday. ... Armstrong Pharmaceutical Inc., because it is the only inhaler ...
... of Kentucky,s Dr. Susanne Arnold and colleagues were awarded a ... reasons for the high lung cancer rates in Eastern Kentucky. ... the study began on Sept. 15. Kentucky has the ... the southeastern portion of the state those in the ...
Cached Medicine News:Health News:New study proposes public health guidelines to reduce the harms from cannabis use 2Health News:New study proposes public health guidelines to reduce the harms from cannabis use 3Health News:Opioids linked to higher risk of pneumonia in older adults 2Health News:Infections Linked to Swimming, Drinking Water: CDC 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 2Health News:In Older Men, Prostate Biopsies Can Raise Risk of Hospitalization 3Health News:Asthma Inhaler Primatene Mist Going Off the Market 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 2Health News:Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky 3
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: